Pediatric Hematology and Oncology Trials

For more information, contact:
Lolie Yu, MPH, MD, at (504) 896-9740
Stephanie Sonnier, RN, at (504) 894-5377

Biology Studies

COG AREN03B2: Children's Oncology Group Renal Tumors Classification, Biology and Banking Study 

ACNS02B3: A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens 

COG ANBL00B1: Neuroblastoma Biology Studies 

COG ACNS02B1: Preclinical Pharmacology in Surgical Brain Tumor Specimens 

AEWS02B1: A Groupwide Biology and Banking Study for Ewing Sarcoma 

P9851: Osteosarcoma Biology Protocol: Companion to Intergroup Therapeutic Studies

Hematopoietic Stem Cell Transplant

Cyclophosphamide Conditioning Regime for Marrow Transplantation from HLA-Identical Family Members for Severe Aplastic Anemia 

Use of Busulfan and Cyclophosphamide as a Transplant Preparative Regimen for Patients with Hematologic Malignancies and Prior Chest Radiotherapy 

Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Children with Bone Marrow Failure Syndromes or Inherited Metabolic or Hematologic Disease 

National Marrow Donor Program (NMDP) Research Database for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries 

PBMTC GVH0313: A Phase II Study of Pentostatin for the Treatment of High-Risk or Refractory Chronic GVHD in Children; A Pediatric Blood and Marrow Transplant Consortium Study 

COG AEWS 0331: European Ewing Tumor Working Initiative of National Groups Ewing Tumor Studies 1999 (EURO-E.W.I.N.G. 99) 

Multicenter Investigation of Sibling Donor Cord Blood Transplantation for Treatment of Symptomatic Sickle Cell Disease or B-Thalassemia Major 

Investigation of HLA-matched, Related, Human Umbilical Cord Blood Transplantation for the Treatment of Symptomatic Sickle Cell Disease or Beta-Thalassemia Major in Children 

COG ASCT0521: Soluble Tumor Necrosis Factor Receptor: Enbrel (Entanercept) for the Treatment of Acute Non-infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation 

A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Children with Hematologic Malignancies 

Selection of CD34+ Cells for Stem Cell Transplantation of Hematologic Malignancies 

A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Non-Myeloablative Preparatory Regimen with Campath-1H, Fludarabine and Melphalan 

PBMTC GVH0112: Cytokine Gene Polymorphisms in Pediatric Patients Receiving Tacrolimus or Cyclosporin for Graft vs. Host Disease Prophylaxis

Brain

ANBL0421: A Phase II Study of Irinotecan + Temozolomide in Children with Recurrent Neuroblastoma 

ACNS0331: A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial 

ANBLOOP2: Perinatal Neuroblastoma: Expectant Observation (A COG Pilot Study) Alternative, Non-Observational Arm 

ANBL 0032: Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

Leukemia

AE24: Epidemiology of Infant Leukemia 

COG AALL03N1: Understanding the Ethnic and Racial Differences in Survival in Children with Acute Lymphoblastic Leukemia 

Use of High Dose Cytosine Arabinoside (ARA-C), Cyclophosphamide, Total Body Irradiation and Marrow Transplantation as Treatment for Patients with Acute Lymphoblastic Leukemia 

COG AALL03B1: Classification of Acute Lymphoblastic Leukemia 

AALL0232: High Risk B-Precursor Acute Lymphoblastic Leukemia 

AALL0331: Standard Risk B-precursor Acute Lymphoblastic Leukemia 

Phase II, Multicenter, Open-Label, Repeat-dose Study of BCX -1777 Infusion in Patients with Advanced T-Cell leukemia with an Option of Long-term BCX -1777 Use (Protocol BCX 1777 -T-04-201) 
Contact: Stacy Valley, CCRC at 504-894-5377 

Phase IIb, Multicenter, Open-Label, Nonrandomized, Repeat Dose Study of Forodesine Hydrochloride in Patients with Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens (Protocol # BCX1777-Tio-05-202 IND 62,777) 
Contact: Stacy Valley, CCRC at 504-894-5377

Lymphoma

COG AHOD0431: A Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Disease 

A5971: Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphobastic Lymphoma or Localized Lymphoblastic Lymphoma; A Phase III Intergroup COG Study 

COG ADOD0031: Phase III Group-Wide Study of Dose-Intensive Response Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease 

COG AHOD 0121: A Phase II/III Study of Immunodulation after High Dose Myeloablative Therapy with Autologous Stem Cell Rescue for Refractory/Relapsed Hodgkin Disease 

High-Dose Cyclophosphamide, Carmustine, and Etoposide and Autologous Bone Marrow Transplantation for Relapsed Hodgkin's Disease

Sarcoma

COG AOST0331: Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy 

COG ARST0431: Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosmamide (VDC) for Patients with High-Risk Rhabdomyosarcoma

Sickle Cell or Beta Thalassemia Major

One Year Open-label, Non-comparative Extension to a Randomized, Multicenter, Phase II Study to Evaluate the Safety and Tolerability, Pharmacokinetics and the Effects on Liver Iron Concentration of Repeated Doses of 5-30 mg/kg/day of ICL670 Relative to Deferoxamine in Sickle Cell Disease Patients with Transfusional Hemosiderosis (Protocol # CICL670A0109E1) 
Contact: Cercre Spence, RN at 504-894-5377 

A Randomized, Open-label, Multi-center, Phase II Study to Evaluate the Safety and Efficacy of Oral ICL670(deferasirox) 20mg/kg/day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients with Iron Overload from Repeated Blood Transfusions (Protocol # CICL6700A2201)
Contact: Cercre Spence, RN at 504-894-5377 

Study of the Significance of Arginine Deficiency on Immune Status in Sickle Cell Disease 

Effect of Immunomodulatory Thalidomide Analogs on the Biosynthesis of Fetal Hemoglobin in Children with Sickle Cell Anemia

Miscellaneous

COG ACCL0423: The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children with Cancer/Treatment Related Cachexia 

COG ABTR01B1: A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors 

ALTE03N1: Key Adverse Events After Childhood Cancer 

COG AEPI041C1: Low Birth Weight and Other Risk Factors for Heptoblastoma 

Epidemiology and Treatment of Circulating Anticoagulants in Patient with Hemophilia and von Willebrand's Disease-the HTRS Registry